The properties and the use of substituted benzofuroxans in pharmaceutical and medicinal chemistry: A comprehensive review

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 8, 2013, Pages 1089-1136

  Jovené, Cyril ^a   Chugunova, Elena A ^b   Goumont, Régis ^a  

^a UNIVERSITÉ DE VERSAILLES SAINT QUENTIN EN YVELINES   (France)

^b Russian Academy of Sciences   (Russian Federation)

Author keywords

10 di n oxide and quinoxaline 1; 4 di n oxide derivatives; Anti bacterial activity; Benzofurazans; Benzofuroxans; Electrochemical studies; Hypoxia selective activity; Meisenheimer complexes; Phenazine 5; Sar studies

Indexed keywords

ANTIMONY; BENZIMIDAZOLE; BENZNIDAZOLE; BENZOFURAZAN DERIVATIVE; CARBADOX; CHLOROQUINE; CYSTEINE; CYTOCHROME P450; DICLOFENAC; DIHYDROPYRIDINE; DIKETONE; DIOXIDINE; ISRADIPINE; KAPPA OPIATE RECEPTOR; MEPACRINE; METRONIDAZOLE; N BROMOSUCCINIMIDE; NIFEDIPINE; NIFURTIMOX; NITROPRUSSIDE SODIUM; PALLADIUM COMPLEX; PHENAZINE DERIVATIVE; QUINOXALINE DERIVATIVE; ROLIPRAM DERIVATIVE; THIOL DERIVATIVE; TIRAPAZAMINE; UNINDEXED DRUG; URIDINE; VANADIUM DERIVATIVE; VASODILATOR AGENT;

ANGINA PECTORIS; ANTIMALARIAL ACTIVITY; ASTHMA; BIOLOGICAL ACTIVITY; BIOTRANSFORMATION; BLOOD PRESSURE; CHAGAS DISEASE; CHEMICAL PHENOMENA; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CYTOTOXICITY; DRUG DESIGN; DRUG INDUSTRY; DRUG MANUFACTURE; ELECTROCHEMICAL ANALYSIS; ELECTRON SPIN RESONANCE; ELECTROPHILICITY; GASTROINTESTINAL DISEASE; HUMAN; LEISHMANIASIS; MALARIA; MINIMUM INHIBITORY CONCENTRATION; MUTAGENICITY; NONHUMAN; OXIDATIVE STRESS; PHYSICAL CHEMISTRY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUBERCULOSIS;

ANIMALS; BENZOXAZOLES; CHEMISTRY, PHARMACEUTICAL; HUMANS;

EID: 84881490887     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557511313080001     Document Type: Review

References (243)

1. Boulton, A.J.; Gosh, P.B. Benzofuroxans. Adv. Heterocycl. Chem., 1969, 10, 1-41
2. Gasco, A.; Boulton, A.J. Furoxans and benzofuroxans. Adv. Heterocycl. Chem., 1981, 29, 251-340.
3. Katritzky, A.R.; Gordeev, M.F. Heterocycles, 1993, 35, 483-518.
4. Lakhdar, S.; Berionni, G.; Goumont, R.; Terrier, F. Understanding the Diels-Alder Reactivity of Superelectrophilic Nitrobenzofuroxans and related 10-Heteroaromatics through DFT-based electrophilicity descriptors. Lett. Org. Chem. 2011, 8, 108-118.
5. Kurbatov, S.V.; Lakhdar, S.; Goumont, R.; Terrier, F. Superelectrophilic 10 Heteroaromatics: New Avenues in SNAr Substitutions, Complexation and Diels-Alder Reactions. Org. Prep. Proced. Int., 2012, 44, 289-339.
6. Kurbatov, S.V.; Rodriguez-Dafonte, P.; Goumont, R.; Terrier, F. Carbon Nucleophilicities of Indoles in SNAr Substitutions of Superelectrophilic 7-Chloro-4,6-dinitrobenzofuroxan and - benzofurazan. J. Org. Chem., 2009, 74, 3305-3315.
7. Ghosh, P.; Ternai, B.; Whitehouse, M. Benzofuroxans and Benzofuroxans: Biochemical and Pharmacological Properties. Med. Res. Rev. 1981, 1, 159-187.
8. Cerecetto, H.; Porcal, W. Pharmacological Properties of furoxans and benzofuroxans: Recent developments. Mini-Rev. Med. Chem., 2005, 5, 57-71.
9. Cerecetto, H.; Gonzalez, M. Benzofuroxan and Furoxan. Chemistry and Biology. Top. Heterocycl. Chem., 2007, 10, 265-308.
10. Sebban, M.; Goumont, R.; Halle, J.C.; Marrot, J.; Terrier, F. Diels- Alder trapping of an o-dinitroso intermediate in the 1-oxide/3-oxide interconversion of 1,2,3-benzoxadiazole derivative. Chem. Commun. 1999, 1009.
11. Ghosh, P.B.; Whitehouse, M.W. Potential antileukemic and immunosuppressive drugs. Preparation and in vitro pharmacological activity of some benzo-2,1,3-oxadiazoles (benzofurazans) and their N-oxides (benzofuroxans). J. Med. Chem., 1968, 11, 305-311.
12. Boulton, A.J.; Katritzky, A.R. A new heterocyclic rearrangement. Proc. Chem. Soc., 1962, 257.
13. Eckert, F.; Rauhut, G.; Katritzky, A.R.; Steel, P.J. A theoretical and experimental study of the molecular rearrangement of 5-methyl-4- nitrobenzofuroxan. J. Am. Chem. Soc., 1999, 121, 6700-6711.
14. Goumont, R.; Jan, E.; Makosza, M.; Terrier, F. Complex Formation and Oxidative Nucleophilic Aromatic Substitution in 4- Nitro-2,1,3-Benzoxadiazole. Org. Biomol. Chem., 2003, 1, 2192-2199.
15. Moutiers, G.; Goumont, R.; Pinson, J.; Terrier, F. Electrochemical oxidation of complex type intermediates in aromatic nucleophilic substitutions. Chem. Eur. J., 2001, 7, 1712-1719.
16. Sebban, M.; Jovene, C.; Sepulcri, P.; Vichard, D.; Terrier, F.; Goumont R. In: Magnetic Resonance Spectroscopy, Donghyun Kim. Ed.; INTECH Publisher, Croatia, 2012, chapter 10, pp. 183-206.
17. Terrier, F.; Lakhdar, S.; Boubaker, T.; Goumont, R. Ranking the reactivity of superelectrophilic heteroaromatics on the electrophilicity scale. J. Org. Chem., 2005, 70, 6242-6253.
18. Forlani, L.; Tocke, A.; Del Vecchio, E.; Lakhdar, S.; Goumont R.; Terrier F. Assessing the Nitrogen and Carbon Nucleophilicities of 2-aminothiazoles through coupling with superelectrophilic 4,6- dinitrobenzofuroxan. J. Org. Chem., 2006, 71, 5527-5537.
19. Lakhdar, S.; Westermaier, M.; Goumont, R.; Boubaker, T.; Mayr, H.; Terrier, F. Nucleophilic Reactivities of Indoles. J. Org. Chem., 2006, 71, 9088-9095.
20. Kurbatov, S.; Rodriguez-Dafonte, P.; Goumont, R.; Terrier, F. Superelectrophilic heterocycles: facile SNAr-SEAr couplings involving very weak carbon nucleophiles. Chem. Commun., 2003, 2150.
21. Haddadin, M.J.; Issidorides, C.H. Application of Benzofurazan Oxide to the Synthesis of Heteroaromatic N-Oxides. Heterocycles, 1976, 4, 767.
22. Haddadin, M.J.; Issidorides, C.H. Benzofuroxan Oxide. II. Reactions with enolate anions. J. Org. Chem., 1966, 31, 4067-4068.
23. Suzuki, H.; Kawakami, T. A convenient synthesis of 3-amino- 1,2,4-benzotriazine-dioxide (SR 4233) and related compounds via nucleophilic aromatic substitution between nitroarenes and guanidine base. Synthesis, 1997, 8, 855-857.
24. Whitehouse, M.W.; Ghosh, P.B. 4-nitrobenzofurazans and 4- nitrobenzofuroxans: a new class of thiol-neutralising agents and potent inhibitors of nucleic acid synthesis in leucocytes. Biochem. Pharmacol., 1968, 17, 158-161.
25. Ghosh, P.B.; Whitehouse, M.W. Potential antileukemic and immunodepressive drugs. II. Further Studies with Benzo-2,1,3- oxadiazoles (benzofurazans) and their N-oxides (Benzofuroxans). J. Med. Chem., 1969, 12, 505-507.
26. Ghosh, P.B., Ternai, B.; Whitehouse, M.W. Potential antileukemic and immunodepressive drugs. 3. Effects of Homocyclic ring substitution on the in vitro drug activity of 4-nitrobenzo-2,1,3-oxadiazoles (4- nitrobenzofurazans) and their N-oxides (4-nitrobenzofuroxans). J. Med. Chem., 1972, 15, 255-260.
27. Terrier, F. Nucleophilic Aromatic Displacement Feuer, H, Ed.; VCH: New York, 1991.
28. Ghosh, P.B.; Everitt, B. Furazanobenzofuroxan, furazanobenzothiadiazole, and their N-oxides. A new class of vasodilatator drugs. J. Med. Chem., 1974, 17, 203-206.
29. Kessel, D.; Belton, J.G. Effects of 4-nitrobenzofurazans and their N-oxides on synthesis of protein and nucleic acid by murine leukemia cells. Cancer Res., 1975, 35, 3735-3740.
30. Strauss, M.J.; Defusco, A.; Terrier, F. Sulfur base complexes of 4,6-dinitrobenzofuroxan. Isolation of the cysteine complexe: support for cellular thiol addition as a primary step in the in vitro inhibition of nucleic acid synthesis by nitrobenzofuroxans. Tetrahedron Lett., 1981, 22, 1945-1948.
31. Metz, J.T.; Huth, J.R.; Hajduk, P.J. Enhancement of chemical rules for predicting compound reactivity towards protein thiol groups. J. Comput. Aided Mol. Des., 2007, 21, 139-144.
32. Nemeikaite-Ceniene, A.; Sarlauskas, J.; Miseviciene, L.; Anusevicius, Z.; Maroziene, A.; Cenas, N. Enzymatic redox reactions of the explosive4,6- dinitrobenzofuroxan (DNBF): implications for its toxic action. Acta Chim. Pol., 2004, 51, 1081-1086.
33. Zhao, J.; Gou, S.; Sun, Y.; Fang, L.; Wang, Z. Antitumor Platinum(II) Complexes Containing Platinum-Based Moieties of Present Platinum Drugs and Furoxan Groups as Nitric Oxide Donors: Synthesis, DNA Interaction, and Cytotoxicity. Inorg. Chem., 2012, 51, 10317-10324.
34. Thompson, S.; Kellicut, L. Mutagenicity of anti-cancer nitrobenzofuroxans. Mutation Res., 1977, 48, 145-154.
35. Belton, J.G.; Conalty, M.L.; O'Sullivan, J.F. Anti-cancer agents-XI anti-tumour activity of 4-amino-7nitrobenzofuroxans and related compounds. Proc. R. Ir. Acad., 1976, 76B, 133-149.
36. Kessel, D. Effects of 4-nitrobenzofuroxans on DNA synthesis by murine leukemia cells. Proc. XI Inter. Cancer Congr., 1974, 127-128.
37. Macphee, D.G.; Robert, G.P.; Ternai, B.; Ghosh, P.; Stephens, R. Mutagenesis by 4-nitrobenzofurazans and furoxans. Chem. -Biol. Interactions, 1977, 19, 77-90.
38. Voogd, C.E.; Van der Stel, J.J.; Jacobs, J.J.J. A.A. The mutagenic action of quindoxin, carbadox, olaquindox and some other Noxides on bacteria and yeast. Mutation Res., 1980, 78, 233-242.
39. Shipton, M.; Brocklehurst, K. Benzofuroxans as a thiol-specific reactivity probe. Kinetic of its reaction with papain, ficin, bromelain and low molecular-weight thiols. Biochem. J., 1977, 167, 799-810.
40. Willenbrock, F.; Brocklehurst, K. Chemical evidence for the pH-dependent control of ion pair geometry in cathepsin B. Benzofuroxans as a reactivity probe sensitive to differences in the mutual disposition of the thiolate and imidazolium components of cysteine proteinase catalytic sites. Biochem. J., 1986, 238, 103-107.
41. Salih, E.; Brocklehurst, K. Investigation oft he catalytic site of actinidin by using benzofuroxan as a reactivity probe with selectivity fort he thiolateimidazolium ion-pair system of cysteine proteinase. Biochem. J., 1983, 213, 713-718.
42. Van den Broeck, L.A.G.M.; Delbressine, L.P.C., Ottenheijm H.C.J. In: Biochemistry and metabolic pathways of sulfenic acids and their derivatives. Edited by S. Patai, John Wiley and Sons Ltd, 1990, Chapter 16, pp. 704-705.
43. Shipton, M.; Stuchbury, T.; Brocklehurst, K.; Herbert, J.A.L.; Suschitzky, H. Evaluation of benzofuroxan as chromophoric oxidizing agent for thiol groups by using its reaction with Papin, Ficin, Bromelain and low-molecularweight thiols. Biochem. J., 1977, 161, 627-637.
44. Norris, S.J.; Edmondson, D.G. Factors affecting the multiplication and subculture of Treponema pallidum subsp. Pallidum in a tissue culture system. Infect. Immun., 1986, 53, 534-539
45. Medana, C.; Di Stilo, A.; Visentin, S.; Fruttero, R.; Gasco, A.; Ghigo, D.; Bosia, A. NO donnor and biological properties of different benzofuroxans. Pharmaceutical Res., 1999, 16, 956-960.
46. Severine, I.S.; Axenova, L.N.; Veselovsky, A.V.; Pyatakova, N.V.; Buneeva, O.A.; Ivanov, A.S.; Medvedev, A.E. Non selective inhibition of monoamine oxidases A and B by activators of soluble guanylate cyclase. Biochemistry (Moscow), 2003, 68, 1048-1054.
47. Bussygina, O.G.; Pyatakova, N.V.; Khropov, Y.V.; Ovchinnikov, I.V.; Makhova, N.N.; Severina, I.S. Benzodifuroxan as NO-dependent activator of soluble guanylate cyclase ad a novel highly effective inhibitor of platelet aggregation. Biochemistry (Moscow), 2000, 65, 457-462.
48. Gasco, A.; Schoenafinger. In: Nitric Oxide Donors. Wang P.G., Cai T.B., Taniguchi N. (eds). Wiley-VCH: Weihelm. 2005, Chapter 6, pp 137-175.
49. Wang, P.G.; Xian, M.; Tang, X.; Wu, X.; Wen, Z.; Cai, T.; Janczuk, A.J. Nitric oxide donnors: chemical activities and biological applications. Chem. Rev., 2002, 102, 1091-1134.
50. Sako, M.; Oda, S.; Ohara, S.; Hirota, K.; Maki, Y. J. Org. Chem., 1998, 63, 6947-6951.
51. Garcia-Ferris, C.; Moreno, J. Redox regulation of enzymatic activity and proteolyc susceptibility of ribulose-1,5-bisphosphate carboxylase/oxygenase from Euglena gracilis. Photosynthesis Res., 1993, 35, 55-66.
52. Low, S.Y. Application of pharmaceuticals to nitric oxide. Molecular Aspect of Medicine, 2005, 26, 97-138
53. Schiefer, I.T.; VandeVrede, L.; Fa, M.; Arancio, O.; Thatcher, G.R.J. Furoxans (1,2,5-oxadiazole-N-oxides) as Novel NO mimetic Neuroprotective and precognitive agents. J. Med. Chem., 2012, 55, 3076-3087
54. Handler, C.E.; Rosenthal, E.; Tsagadopoulos, D.; Najm, Y. Comparison of isradipine and nifedipine in chronic stable angina. Intl. J. Cardiol.,1998, 18, 15-26.
55. Nagarathnam, D.; Miao, S.H.; Lagu, B.; Chiu, G.; Fang, J.; Murali Dhar, T.G.; Zhang, J.; Tyagarajan, S.; Marzabadi, M.R.; Zhang, F.; Wong, W.C.; Sun, S.; Tian, D.; Wetzel, J.M.; Forray, C.; Chang, R.S.L.; Broten, T.P.; Ransom, R.W.; Schorn, T.W.; Chen, T.B.; O'Malley, S.; Kling, P.; Schneck, K.; Bendesky, R.; Harrell, C.M.; Vyas, K.P.; Gluchowski, C. Design and synthesis of novel 1a Adrenoceptor-selective antagonists. 1. Structure-Activity Relationship in Dihydropyrimidinones. J. Med. Chem., 1999, 423, 4764-4777.
56. Atwal, K.S.; Rovnyak, G.C.; Schwartz, J.; Moreland, S.; Hedberg, A.; Gougoutas, J.Z.; Malley, M.F.; Floyd, D.M. Dihydropyrimidines Calcium channel blockers: 2-heterosubstituted 4-aryl-1,4-dihydro-6- methyl-5-pyrimidinecarboxylic acid esters as potent mimics of dihydropyridines. J. Med. Chem., 1990, 33, 1510-1515.
57. Atwal, K.S.; Rovnyak, G.C.; Kimball, S.D.; Floyd, D.M.; Moreland, S.; Swanson, B.N.; Gougoutas, J.Z.; Schwartz, J.; Smillie, K.M.; Malley, M.F. Dihydropyrimidines Calcium channel blockers: 2. 3- substituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic acid esters as potent mimics of of dihydropyridines. J. Med. Chem., 1990, 33, 2629-2635.
58. Elliott, J.M.; Selnick, H.G.; Claremon, D.A.; Bladwin, J.J.; Buhrow, S.A.; Butcher, J.W.; Habecker, C.N.; King, S.W.; Lynch, J.J.; Phillips, B.T.; Ponticello, G.S.; Radzilowski, E.M.; Remy, D.C.; Stein, R.B.; White, J.I.; Young, M.B. 4-oxospiro [benzopyran-2,4'-piperidines] as Class III antiarrhythmic agents. Pharmacological Studies on 3,4-dihydro-1'-[2-(benzofurazan-5-yl)- ethyl]-6-methanesulfonamidospiro[(2H)-1-benzopyran-2,4'- piperidin]-4-one. J.Med. Chem., 1992, 35, 3973-3976.
59. Cross, P.E.; Arrowsmith, J.E.; Thomas, G.N.; Gwilt, M.G.; Burges, R.A.; Higgins A.J. Selective Class III antiarrhythmic agents. 1. Bis(arylalkyl)amines. J.Med. Chem., 1990, 33, 1151-1155.
60. Pfizer, Ltd. UK-68,798. Drugs of the Future, 1991, 16, 521-526.
61. Gasco, A.M.; Ermondi, G.; Fruttero, R.; Gasco, A. Benzofurazanyl- and benzofuroxanyl-1,4-dihydropyridines: synthesis, structure and calcium entry blocker activity. Eur. J. Med. Chem., 1996, 31, 3-10.
62. Hof, R.P.; Vogel, A. Isropidine. Drugs of the Future, 1985, 10, 746-747.
63. Neumann, P. Ger. Offen. 2, 1980, 949, 464.
64. Visentin, S.; Amiel, P.: Fruttero, R.; Boschi, D.; Roussel, C.; Giusta, L.; Carbone, E.; Gasco, A. Synthesis and voltage-clamp studies of methy1,4-dihydro-2,6-dimethyl-5-nitro-4-(benzofurazanyl) pyridine-3-carboxylate racemates and enantiomers and of their benzofuroxanyl analogues. J.Med. Chem., 1999, 42, 1422-1427.
65. Ermondi, G.; Visentin, S.; Boschi, D.; Fruttero, R.; Gasco, A. Structural investigation of Ca2+ antagonists benzofurazanyl and benzofuroxanyl-1,4-dihydropyridines. J.Mol. Struct., 2000, 523, 149-162.
66. Triggle, D.J.; Langs, D.A.; Janis, R.A. Ca2+ channel ligands: structure-function relationships of the 1,4-dihydropyridines. Med. Res. Rev., 1989, 9, 123-180.
67. Goldmann, S.; Stoltefuss, J. 1,4-dihydropyridines: effects of chirality and conformation on the calcium antagonist and calcium agonist activities. Angew. Chem. Int. Ed. Engl., 1991, 30, 1559-1578.
68. Rovnyak, G.C.; Kimball, S.D.; Beyer, B.; Cucinotta, G.; Marco, J.D.; Gougoutas, J.; Hedberg, A.; Malley, M.; McCarthy, J.P.; Zhang, R.; Moreland, S. Calcium entry blockers and activators: conformational and structural determinants of dihydropyrimidine calcium channel modulators. J.Med. Chem., 1995, 38, 119-129.
69. Wie, X.Y.; Luchowski, E.M.; Rutledge, A.; Su, C.M.; Triggle, D.J. Pharmacologic and radioligand binding analysis of the actions of 1,4-dihydropyridine activator-antagonist pairs in smooth muscle. J. Pharmacol. Exp. Ther., 1986, 239,144-153.
70. Vo, D.; Nguyen, J.T.; McEwen, C.A.; Shan, R.; Knaus, E.E. Syntheses, calcium channel modulation effects, and nitric oxide release studies of [3-(benzenesulfonyl)furoxan-4-yloxy]alkyl 1,4- dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl, benzofurazan-4-yl, 2-, 3-, or 4-pyridyl)-3-pyridine-5-carboxylates. Drug Dev. Res., 2002, 56, 1-16.
71. Velazquez, C.; Vo, D.; Knaus, E.E. Syntheses, calcium channel modulation effects, and nitric oxide release studies of O2-alkyl-1- (pyrrolidin-1-yl) diazen-1-ium-1,2-diolate 4-Aryl(heteroaryl)-1,4- dihydro-2,6-dimethyl-3-nitropyridine-5-carboxylates. Drug Dev. Res., 2003, 60, 204-216.
72. Velazquez, C.; Knaus, E.E. Bioorg. Synthesis and biological evaluation of 1,4-dihydropyridine calcium channel modulators having a diazen-1-ium-1,2-diolate nitric oxide donor moiety for the potential treatment of congestive heart failure. Med. Chem., 2004, 12, 3831-3840.
73. Cavalli, M.L. Bolognesi, J.Med. Chem., 2009, 52, 7339.
74. O'Connell, D. Neglected diseases. Nature, 2007, 449, 157.
75. Hotez, P.; Molyneux, D.H.; Fenwick, A.; Ottesen, E.; Sachs, S.E.; Sachs, J.D. Incorporating a rapid impact package for neglected tropical diseases with programmes for HIV/AIDS, tuberculosis and malaria. PLos Med. 2006, 3, e102.
76. Cazzulo, J.J. Proteinases of Trypanosoma Cruzi: Potential targets for the chemotherapy of Chagas disease. Curr. Top. Med. Chem., 2002, 2,1261-1271.
77. Hotez, P.; Molyneux, D.H.; Fenwick, A.; Kumaresan, J.; Sachs, S.E.; Sachs, J.D.; Savioli, L. Control of neglected tropical diseases. N. Engl. J. Med. 2007, 357, 1018-1027.
78. Cerecetto, H.; Di Maio, R.; Gonzales, M.; Risso, M.; Saenz, P.; Seoanne, G.; Denicola, A.; Peluffo, G.; Quijano, C.; Olea-Azar, C. 1,2,5-oxadiazole N-oxide derivatives and related compounds as potential antitrypanosomal drugs: structure-activity relationships. J. Med. Chem., 1999, 42, 1941-1950.
79. Aguirre, G.; Cerecetto, H.; Di Maio, R.; Gonzales, M.; Porcal, W.; Seoanne, G.; Ortega, M.A.; Aldana, I.; Monge, A.; Denicola, A. Benzo[1,2-c]1,2,5oxadiazole N-oxide derivatives as potential antitrypanosomal drugs: structure-activity relationships. Part II. Arch. Pharm. Pharm. Med. Chem., 2002, 335, 15-21.
80. Du, X.; Hansell, E.; Engel, J.C.; Caffrey, C.R.; Cohen, F.E.; McKerrow, J.H. Aryl ureas represent a new class of antitrypanosomal agents. Chem. Biol. 2000, 7, 733-742.
81. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Feliver. Rev., 1997, 23, 3-25.
82. Olea-Azar, C.; Rigol, C.; Opazo, L.; Morello, A.; Maya, J.D.; Repetto, Y.; Aguirre, G.; Cerecetto, H.; Di Maio, R.; Gonzales, M.; Porcal, W. ESR and spin trapping studies of two new potential antitrypanosomal drugs. J. Chil. Chem. Soc., 2003, 48, 77-84.
83. Olea-Azar, C.; Rigol, C.; Mendizabal, F.; Cerecetto, H.; Di Maio, R.; Gonzales, M.; Porcal, W. A. Morello, A.; Repetto, Y.; Maya, J.D. Novel Benzo[1,2-c]1,2,5oxadiazole N-oxide derivatives as antichagasic agents: chemical and biological studies. Lett. Drug Des. Discov., 2005, 2, 294-301.
84. Gervasio, G.; Marabello, D.; Bertolotti, F. o-benzoquinone dioxime. Acta Cryst., 2010, E66, o2764.
85. Aguirre, G.; Boiani, L.; Cerecetto, H.; Di Maio, R.; Gonzales, M.; Porcal, W.; Denicola, A.; Möller, M.; Thomson, L.; Tortora, V. Benzo[1,2-c]1,2,5oxadiazole N-oxide derivatives as potential antitrypanosomal drugs. Part 3: substituents-clustering methodology in the search for new active compounds. Bioorg. Med. Chem., 2005, 13, 6324-6335.
86. Hansch, C.; Unger, S.H.; Forsythe, A.B. Strategy in drug design. Cluster analysis as an aid in the selection of substituents. J. Med. Chem., 1973, 16, 1217-1222.
87. Aguirre, G.; Boiani, L.; Boiani, M.; Cerecetto, H.; Di Maio, R.; Gonzales, M.; Porcal, W.; Denicola, A.; Piro, O.E.; Castellano, E.E.; Mauricio, C.; Sant'Anna, R.; Barreiro, E.J. New potent 5- substituted benzofuroxans as inhibitors of trypanosoma cruzi growth: quantitative structure-activity relationship studies. Bioorg. Med. Chem., 2005, 13, 6336-6346.
88. Boiani, M.; Cerecetto, H.; Gonzales, M.; Gasteiger, J. Modeling antitrypanosoma cruzi activity of N-oxide containing heterocycles. J. Chem. Inf. Model., 2008, 48, 213-219.
89. Porcal, W.; Hernandez, P.; Aguirre, G.; Boiani, L.; Boiani, M.; Merlino, A.; Ferreira, A.; Di Maio, R.; Castro, A.; Gonzales, M.; Cerecetto, H. Second generation of 5-ethenylbenzofuroxan derivatives as inhibitors of trypanosoma cruzi growth: synthesis, biological evaluation, and structure-activity relationships. Bioorg. Med. Chem., 2007, 15, 2768-2781.
90. Porcal, W.; Hernandez, P.; Aguirre, G.; Boiani, L.; Boiani, M.; Chidichimo, A.; Cazzulo, J.J.; Campillo, N.E.; Paez, J.A.; Castro, A.; Luise Krauth-Siegel, R.; Davies, C.; Basombrio, M.A.; Gonzales, M.; Cerecetto, H. In vivo Anti-Chagas vinylthio-, vinylsulfinyl, and vinylsulfonylbanzofuroxan derivatives. J. Med. Chem., 2007, 50, 6004-6015.
91. Porcal, W.; Hernandez, P.; Boiani, L.; Boiani, M.; Ferreira, A.; Chidichimo, A.; Cazzulo, J.J.; Olea-Azar, C.; Gonzales, M.; Cerecetto, H. New trypanocidal hybrid compounds from the association of hydrazone moieties and benzofuroxan heterocycle. Bioorg. Med. Chem., 2008, 16, 6995-7004.
92. Rivera, G., Bocanegra-Garcia, V.; Ordaz-Pichardo, C.; Nogueda-Torres, B.; Monge, A. New therapeutic targets for drug design againts Trypanosoma cruzi, advances and perspectives. Curr. Med. Chem., 2009, 16, 3286-3293.
93. Castro, D.; Boiani, L.; Benitez, D.; Hernandez, P.; Merlino, A.; Gil, C.; Olea-Azar, C.; Aguirre, G.; Gonzales, M.; Cerecetto, H.; Porcal, W. Anti_trypanosomatid benzofuroxans and deoxygenated analogues: synthesis using polymer supported triphenylphosphine, biological evaluation and mechanism of action studies. Eur. J. Med. Chem., 2009, 44, 5055-5065.
94. W. Porcal, A. Merlino, M. Boiani, A. Gerpe, M. Gonzales, M.; Cerecetto, H. Arylethenylbenzofuroxan derivatives as drugs for Chagas diseases: multigram batch synthesis using a Wittig-Boden process. Org. Process Res. Dev., 2008, 12, 156-162.
95. Boiani, L.; Davies, C.; Arredondo, C.; Porcal, W.; Merlino, A.; Gerpe, A.; Boiani, M.; Pacheco, J.P.; Basombrio, M.A.; Gonzales, M.; Cerecetto, H. In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas disease. Eur. J. Med. Chem., 2008, 43, 2229-2237.
96. Martins, F.T.; Ayala, A.P.; Porcal, W.; Gonzales, M.; Cerecetto, H.; Ellena, J. Structural relationships in the solid state of the antichagas agent (E)-phenylethenylbenzofuroxan. Mol. Divers., 2010, 14, 643-652.
97. Cabrera, M.; Lavaggi, M.L.; Hernandez, P.; Merlino, A.; Gerpe, A.; Porcal, W.; Boiani, M.; Ferreira, A.; Monge, A.; Lopez de Cerain, A.; Gonzales, M.; Cerecetto, H. Cytotoxic, mutagenic and genotoxic effects of new anti-T. cruzi 5-phenylethenylbenzofuroxans. Contribution of phase I metabolites on the mutagenicity induction. Toxicol. Lett., 2009, 190, 140-149.
98. Boiani, M.; Merlino, A.; Gerpe, A.; Porcal, W.; Croce, F.; Depaula, S. o-nitroanilines as major metabolic products of anti-Trypanosoma cruzi 5-phenylethenylbenzofuroxans in microsomal and cytosolic fractions of rat hepatocytes and in whole parasitic cells. Xenobiotica, 2009, 39, 236-248.
99. Grosa, G.; Galli, U.; Rolando, B.; Fruttero, R.; Gervasio, G.; Gasco, A. Identification of 2,3-diaminophenazine and obenzoquinone dioxime as the major in vitro metabolites of benzofuroxan. Xenobiotica, 2004, 34, 345-352.
100. Boiani, M.; Piacenza, L.; Hernandez, P.; Boiani, L.; Cerecetto, H.; Gonzales, M.; Denicola, A. Mode of action of Nifurtimox and Noxide- containing heterocycles against Trypanosoma cruzi: is oxidative stress involved? Biochem. Pharmacol., 2010, 79, 1736-1745.
101. Alvarez, G.; Aguirre-Lopez, B.; Varela, J.; Cabrera, M.; Merlino, A.; Lopez, G.V.; Lavaggi, M.L.; Porcal, W.; Di Maio, R.; Gonzales, M.; Cerecetto H.; Cabrera, N.; Perez-Montfort, R.; Tuena de Gomez-Puyou, M., Gomez-Puyou, A. Massive screening yields novel and selective Trypanosoma cruzi triosephosphate isomerase dimer-interface-irreversible inhibitors with antitrypanosomal activity. Eur. J. Med. Chem., 2010, 45, 5767-5772.
102. Merlino, A.; Benitez, D.; Chavez, S.; Da Cunha, J.; Hernandez, P.; Tinoco, L. W., Campillo, N. E.; Paez, J.A.; Cerecetto H.; Gonzales, M. Development of second generation amidinohydrazones, thio- and semicarbazones as Trypanosoma cruzi-inhibitors bearing benzofuroxan and benzimidazole 1,3-dioxide scaffolds. Med. Chem. Commun., 2010, 1, 216-228.
103. Merlino, A.; Benitez, D.; Campillo, N. E.; Paez, J.A.; Tinoco, L. W.; Gonzales, M.; Cerecetto, H. Amidines bearing benzofuroxan or benzimidazole 1,3-dioxide core scaffolds as Trypanosoma cruziinhibitors: structural basis for their interactions with cruzipain. Med. Chem. Commun., 2012, 3, 90-101.
104. Jorge, S.D.; Ishii, M.; Palace-Berl, F.; Ferreira, A.K.; de Sa, P.L.; de Oliveira, A.A.; Sonehara, I.Y.; Pasqualoto, K.F.M.; Tavares, L.C. Preliminary in vitro evaluation of N'-(benzofuroxan-5-yl)methylene benzohydride derivatives as potential Trypanosoma cruzi agents. Med. Chem. Commun., 2012, 3, 824-828.
105. Gerpe, A.; Boiani, L.; Hernandez, P.; Sortino, M.; Zacchino, S.; Gonzales, M.; Cerecetto, H. Naftifine analogues as anti- Trypanosoma cruzi agents. Eur. J. Med. Chem., 2010, 45, 2154-2164.
106. Schieferstein, R.H.; Pilgram, K. Herbicidal activity of 2,1,3- benzothiadiazolecarbonitriles and related cyanoheterocycles. J. Agric. Food Chem., 1975, 23, 392-395.
107. Cerecetto, H.; Dias, E.; Di Maio, R.; Gonzales, M.; Pacce, S.; Saenz, P.; Seoane, G. Synthesis and herbicidal activity of N-oxide derivatives. J. Agric. Food Chem., 2000, 48, 2995-3002.
108. Medana, C.; Visentin, S.; Grosa, G.; Fruttero, R.; Gasco, A. Nitroanilines are the reduction products of benzofuroxan system by oxyhemoglobin (HbO 2 2 +). Il Farmaco, 2001, 56, 799-802.
109. Deghati, P.Y.F.; Borghini, A.; Van den Nieuwendijk, A.M.C.H., Dissen-de Groote, M.; Ijzerman, A.P. Inhibition of nucleoside transport by new analogues of nitrobenzylthioinosine. Bioorg. Med. Chem., 2003, 11, 899.
110. Montana, J.G.; Cooper, N.; Dyke, H.J.; Gowers, L.; Gregory, J.P.; Hellewell, P. G.; Miotla, J.; Morris, K.; Naylor, R.J.; Tuladhar, B.; Warneck, J.B.H. PDE4 inhibitors: new xanthine analogues. Bioorg. Med. Chem., 1998, 8, 2925-2930.
111. Montana, J.G.; Buckley, G.M.; Cooper, N.; Dyke, H.J.; Gowers, L.; Gregory, J.P.; Hellewell, P. G.; Kendall, H.J.; Lowe, C.; Maxey, R.; Miotla, J.; Naylor, R.J.; Runcie, K.A.; Tuladhar, B.; Warneck, J.B.H. Aryl sulfonamides as selective PDE4 inhibitors. Bioorg. Med. Chem., 1998, 8, 2635-2640.
112. Manley, P.W.; Acemoglu, M.; Marterer, W.; Pachinger, W. Largescale Negishi coupling as applied to the synthesis of PDE472, an inhibitor of Phosphodiesterase type 4D. Org. Process Res. Dev., 2003, 7, 436-445.
113. Manley, P.W.; Bray, K.; Floersheim, P.; Mazzoni, L.; Müller, T. PDE 4 inhibitors: design, synthesis and anti-inflammatory activity of 4-(3-cyclopentylidinemethyl-4-methoxy-phenyl)pyridine. Chimia, 1996, 50, 312.
114. De Carvalho, P.S.; Marostica, M.; Gambero, A.; Pedrazzoli Jr., J. Synthesis and pharmacological characterization of a novel nitric oxide releasing diclofenac derivative containing a benzofuroxan moiety. Eur. J. Med. Chem., 2010, 45, 2489-2493.
115. Jorge, S.D.; Masunari, A.; Oliveira Rangel-Yagui, C.; Mesquita Pasqualoto, K.F.; Costa Tavares, L. Design, synthesis, antimicrobial activity and molecular modeling studies of novel benzofuroxan derivatives against Staphylococus aureus. Bioorg. Med. Chem., 2009, 17, 3028-3035.
116. Jorge, S.D.; Palace-Berl, F.; Masunari, A.: Cechinel, C.A.; Ishii, M.; Mesquita Pasqualoto, K.F.; Costa Tavares, L. Novel benzofuroxan derivatives against multidrug-resistant Staphylococus aureus: design using topliss' decision tree, synthesis and biological assay. Bioorg. Med. Chem., 2011, 19, 5031-5038.
117. Kumar, V.; Guo, D.; Daubert, J.D.; Cassel, J.A.; DeHaven, R.N.; Mansson, E.; DeHaven-Hudkins, D.L.; Maycock, A.L. Amino acid conjugates as κ opioid receptor agonists. Bioorg. Med. Chem. Lett., 2005, 15, 1279-1282.
118. Sartini, S.; Cosconati, S.; Marinelli, L.; Barresi, E.; Di Maro, S.; Simorini, F.; Taliani, S.; Salerno, S.; Marini, A.M.; Da Settimo, F.; Novellino, E.; La Motta, C. Benzofuroxan derivatives as multi effective agents for the treatment of cardiovascular diabetic complications. Synthesis, functional evaluation and molecular modeling studies. J. Med. Chem., 2012, 55, 10523-10531.
119. Cosconati, S.; Marinelli, L.; La Motta, C.; Sartini, S.; Da Settimo, F.; Olson, A.J.; Novellino, E. Pursuing Aldose Reductase Inhibitors through in Situ Cross-Docking and similarity-Based Virtual Screening. J. Med. Chem., 2009, 52, 5578-5581.
120. Chugunova, E.A.; Sazykina, M.A.; Gibadullina, E.M.; Burilov, A.R.; Sazykin, I.S.; Chistyakov, V.A.; Timasheva, R.E.; Krivolapov, D.B.; Goumont, R. Synthesis, genotoxicity and UVprotective activity of new benzofuroxans substituted by aromatic amines. Lett. Drug Des. Discov., 2013, 10, 145-154.
121. Haddadin, M.F. Issidores, C.H. Enamines with isobenzofuroxan: a novel type of quinoxaline-di-N-oxides. Tet. Lett., 1965, 36, 3253-3256.
122. Abu El-Haj, M.J.; Dominy, B.W.; Johnston, J.D.; Haddadin, M.F.; Issidores, C.H. A new route to phenazine 5,10-dioxides and related compounds. J. Org. Chem., 1972, 37, 589-593.
123. McFarland, J.W. 2,3-dihydroquinoxaline 1,4-dioxides as Intermediates in the reaction between Benzofuroxan 1-oxide and enamines. J. Org. Chem., 1970, 35, 1842-1843.
124. Kluge, A.F.; Maddox, M.L.; Lewis, G.S. Formation of Quinoxaline Monoxides from reaction of benzofurazan oxide with enones and 13C NMR correlations of Quinoxaline N-oxides. J. Org. Chem., 1980, 45, 1909-1914.
125. Stumm, G.; Niclas, H.J.; Winter, G.; Reck, G. Synthesis and structure of quinoxaline-substituted 1,4- dihydropyridines. Arch. Pharm. Pharm. Med. Chem., 1991, 324, 971-978.
126. El-Abadelah, M.M.; Sabri, S.S., Nazer, M.Z.; Za'ater, M.F. Synthesis and chirooptical properties of some N-(3-methyl-2- quinoxaloyl) L-aminoacids and their dioxides. Tetrahedron, 1976, 32, 2931-2938.
127. Abushanab, E. Quinoxaline 1,4-dioxides. Nucleophilic of sulfinyl and sulfonyl groups in acid media. A novel method for the preparation of 2-haloquinoxaline 1,4-dioxides. J. Org. Chem., 1973, 38, 3105-3107.
128. Cerecetto, H., Gonzales, M.; Laura-Lavaggi, M.; Porca, W. Preparation of phenazine N5,N10-dioxides. Effects of Benzofuroxan substituents in the outcome of their expansion reaction with phenolates. J. Braz. Chem.Soc., 2005, 16, 1290-1296.
129. Takeuchi, S.; Saito, H.; Miyrairi, S.; Takabatake, T. Molecular sieves catalyzed synthesis of phenazine-5,10-dioxides under solvent-free conditions using microwave irradiation. Heterocycles, 2011, 83, 531-534.
130. Gomez-Caro, L.C.; Sanchez-Sanchez, M., Bocanegra-Garcia, V.; Rivera, G.; Monge, A. Synthesis of quinoxaline 1,4-di-oxide derivatives on solid support using room temperature and microwave-assisted solvent-free procedures. Quim. Nova, 2011, 34, 1147-1151.
131. Dahbi, S.; Methnani, E.; Bisseret, P. First Synthesis of 2-phosphonylated quinoxaline 1,4- dioxides: an extension to the Beirut reaction. Tetrahedron Lett., 2010, 51, 5516-5520.
132. Dahbi, S.; Bisseret, P. Near room temperature cross-couplin reactions of arene boronic acids with a quinoxaline 1,4-dioxide benzylsulfanyl derivative. Eur. J. Org. Chem., 2012, 3759-3763.
133. Lima, L.M.; Vicente, E.; Solano, B.; Perez-Silanes, S.; Aldana, I.; Monge, A. Unexpected Reduction of ethyl 3- phenylquinoxaline-2-carboxylate 1,4-di-N-oxide derivatives by amines. Molecules, 2008, 13, 78-85.
134. Vicente, E.; Villar, R.; Burguete, A.; Ancizu, S.; Perez-Silanes, S.; Aldana, I.; Monge, A. Substitution of fluorine atoms and phenoxy groups in the synthesis of quinoxaline 1,4-di-N-oxide derivatives. Molecules, 2008, 13, 86-95
135. Abu El-Haj, M.J. Novel Synthesis of 1-hydroxy-1-Hbenzimidazole 3-oxides and 2,2-dialkyl-2H-benzimidazole 1,3-dioxides. J. Org. Chem., 1972, 37, 2519-2520.
136. Seng, F.; Ley, K. Simple synthesis of 3-amino-1,2,4-benzotriazine 1,4-dioxide. Angew. Chem. Internat. Edit., 1972, 11, 1009-1010.
137. Chen, Y.; Hu, L. Design of anticancer prodrugs for reductive activation. Med. Res. Rev., 2009, 29, 29-64.
138. McIlwain, H. Bacterial inhibition by metabolite analogues. Part V. Reactions and antibacterial properties of p-Diazine Di-N-oxides. J. Chem. Soc., 1943, 322-325.
139. Landquist, J.K.; Levi, A.A.; Silk, J.A., Thorp, J.M. 2-hydroxymethyl-3-methylquinoxaline 1:4- Dioxide: a Metabolite of 2:3-dimethylquinoxaline 1:4-dioxide active against Gram-negative Bacteria. Biochem. J., 1956, 63, 455-457.
140. Edwards, M.L.; Bambury, R.E.; Ritter, H.W. β-lactam antibiotics with N-Oxide side chains. 1. Quinoxaline N-oxides. J. Med. Chem., 1976, 19, 330-333.
141. Edwards, M.L.; Bambury, R.E.; Ritter, H.W. 3-substituted 2- fromylquinoxaline 1,4-dioxides. J. Med. Chem., 1975, 18, 637-639.
142. Thrasher, G.W; Shiveley, J.E.; Askelson, C.E. Effects of carbadox on performance and carcass traits of growing swine. J. Am. Chem. Soc., 1970, 31, 333-338.
143. McIlwain, H. The anti-streptococcal action of iodinin. Naphtoquinones and anthraquinones as its main natural antagonist. Biochem J. 1943, 37, 265-271.
144. Weigele, M.; Leimgruber, W. The structure of Myxin. Tet. Lett., 1967, 8, 715-718.
145. Oda, M., Sekizawa, Y.; Watanabe, T. Phenazines as disinfectants against bacterial leaf blight of the rice plant. Appl. Microbiol., 1966, 14, 365-367.
146. Chowdhury, G.; Sarkar, U.; Pullen, S.; Wilson, W.R.; Rajapakse, A.; Fuchs-Knotts, T.; Gates, K.S. DNA strand cleavage by the phenazine Di-N-oxide natural product Myxin under both aerobic and anaerobic conditions. Chem. Res. Toxicol., 2012, 25, 197-206.
147. Zeman, E.M.; Brown, J.M.; Hirst, V.K.; Lee, W.W. SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mamalian cells. Int. J. Radiat. Oncol. Biol. Phys., 1986, 17, 1239-1242.
148. Laursen, J.B.; Nielsen, J. Phenazine Natural Products: Biosynthesis, Synthetic Analogues and biological activity. Chem. Rev., 2004, 104, 1663-1685.
149. Deepika, Y.; Surendra Nath, P.; Sachin, K.; Shewta, S. Biological activity of quinoxaline derivatives. Int. J. Curr. Pharm. Rev. Res., 2011, 1, 33-46.
150. Carta, A.; Corona, P.; Loriga, M. Quinoxaline 1,4-dioxide: a versatile endowed with manifold activities. Curr. Med. Chem., 2005, 12, 2259-2272.
151. Gonzales, M.; Cerecetto, H.; Monge, A. Quinoxaline 1,4- dioxides and phenazine 5,10-dioxide. Chemistry and biology. Top Heterocycl. Chem., 2007, 11, 179-211.
152. Gonzales, M.; Cerecetto, H. Quinoxaline derivatives: a patent review (2006-present). Expert Opin. Ther. Patents, 2012, 22, 1289-1302.
153. Suter, W.; Rosselet, A.; Knusel, F. Mode of action of quindoxin and substituted quinoxaline-di-oxides on Escherichia coli. Antimicrob. Agents Chemother., 1978, 13, 770-783.
154. Beutin, L.; Preller, E.; Kowalski, B. Mutagenicity of quindoxin, its metabolites, and two substituted quinoxaline-di-N-oxides. Antimicrob. Agents Chemother., 1981, 20, 336-343.
155. Glazer, E.A.; Chappel, L.R. Pyridoquinoxaline N-oxides. 1. A new class of antichromonal agents. J. Med. Chem., 1982, 25, 766-769.
156. Loriga, M.; Nuvole, A.; Paglietti, G.; Fadda, G.; Zanetti, S. 2-Phenyl-6(7)-R-substituted quinoxalines N-oxides. Synthesis, structure elucidation and antimicrobial activity. Eur. J. Med. Chem., 1990, 23, 527-532.
157. Glazer, E.A.; Presslitz, J.E. Pyridoquinoxaline N-oxides. 2. Synthesis and antibacterial activity of tricyclic lactams. J. Med. Chem., 1982, 25, 868-870.
158. Dirlam, J.P.; Presslitz, J.E. Synthesis and antibacterial activity of isomeric 6- and 7-acetyl-3-methyl-2-quinoxalinecarboxamide 1,4- dioxides. J. Med. Chem., 1978, 21, 483-485.
159. Aldana, I.; Ortega, M.A.; Jaso, A.; Zarranz, B.; Oporto, P.; Gimenez, A.; Monge, A.; Deharo, E. Anti-malarial activity of some 7-chloro-2-quinoxalinecarbonitrile-1,4-di-N-oxide derivatives. Pharmazie, 2002, 58, 68-69.
160. Zarranz, B.; Jaso, A.; Aldana, I.; Monge, A.; Maurel, S.; Deharo, E.; Jullian, V.; Sauvain, M. Synthesis and Antimalarial Activity of New 3-Arylquinoxaline-2-carbonitrile Derivatives. Arzneim. Forsch/Drug Res. 2005, 55, 754-761.
161. Lima, L.M.; Zarranz, B.; Marin, A.; Solano, B.; Vicente, E.; Perez-Silanes, S.; Aldana, I.; Monge, A. Comparative Use of solvent-free KF-Al2O3 and K2CO3 in acetone in the synthesis of quinoxaline 1,4-dioxide derivatives designed as antimalarial drug candidates. J. Heterocyclic Chem., 2005, 42, 1381-1385.
162. Vicente, E.; Lima, L.M.; Bongard, E.; Charneau, S.; Villar, R.; Solano, B.; Burguete, A.; Perez-Silanes, S.; Aldana, I.; Vivas, L.; Monge, A. Synthesis and Structure-activity relationship of 3- phenhylquinoxaline 1,4-di-N-oxide derivatives as antimalarial agents. Eur. J. Med. Chem., 2008, 43, 1903-1910.
163. Marin, A.; Lima, L.M.; Solano, B.; Vicente, E.; Perez-Silanes, S.; Maurel, S.; Sauvain, M.; Aldana, I.; Monge, A.; Deharo, E. Antiplasmodial structure-activity relationship of 3-trifluoromethyl- 2-arylcarbonylquinoxaline 1,4-di-N-oxide derivatives. Exp. Parasitol., 2008, 118, 25-31.
164. Zarranz, B.; Jaso, A.; Lima, L.M.; Aldana, I.; Monge, A.; Maurel, S.; Sauvain, M. Antiplasmodial activity of 3-trifluoromethyl-2-carbonylquinoxaline di-N-oxide derivatives. Braz. J. Pharm. Sci., 2006, 42, 357-361.
165. Vicente, E.; Charnaud, S.; Bongard, E.; Villar, R.; Burguete, A.; Solano, B.; Ancizu, S.; Perez-Silanes, S.; Aldana, I.; Vivas, L.; Monge, A. Synthesis and antiplasmodial activity of 3-furyl and 3- thienylquinoxaline-2-carbonitrile 1,4-Di-N-oxide derivatives. Molecules, 2008, 13, 69-77.
166. Barea, C.; Pabon, A.; Castillo, D.; Zimic, M.; Quiliano, M.; Galiano, S.; Perez-Silanes, S.; Monge, A.; Deharo, E.; Aldana, I. New salicylamide and sulfonamide derivatives of quinoxaline 1,4-di-N-oxide with antileishmanial and antimalarial activities. Bioorg. Med. Chem. Lett., 2011, 21, 4498-4502.
167. Barea, C.; Pabon, A.; Galiano, S.; Perez-Silanes, S.; Gonzales, G.; Deyssard, C.; Monge, A.; Deharo, E.; Aldana, I. Antiplasmodial and leishmanicidal activities of 2-cyano-3-(4-phenylpiperazine-1- carboxamido) quinoxaline 1,4-dioxide derivatives. Molecules, 2012, 17, 9451-9461.
168. Burguete, A.; Estevez, Y.; Castillo, D.; Gonzales, G.; Villar, R.; Solano, B.; Vicente, E.; Perez-Silanes, S.; Aldana, I.; Monge, A.; Sauvain, M.; Deharo, E. Anti-leishmanial and structure-activity relationship of ring substituted 3-phenyl-1-(1,4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one derivatives. Mem. Inst. Oswaldo Cruz, 2008, 103, 778-780.
169. Ortega, M.A.; Montoya, M.E.; Jaso, A.; Zarranz, B.; Tirapu, I.; Aldana, I.; Monge, A. Antimycobacterial activity of new quinoxaline-2-carbonitrile and quinoxaline-2-carbonitrile 1,4- dioxide derivatives. Pharmazie, 2001, 56, 205-207.
170. Ortega, M.A.; Sainz, Y.; Montoya, M.E.; Jaso, A.; Zarranz, B.; Aldana, I.; Monge, A. Anti-mycobacterium tuberculosis agents derived from quinoxaline-2-carbonitrile and quinoxaline-2-carbonitrile 1,4- dioxide. Arzneim. Forsch/Drug Res. 2002, 52, 113-119.
171. Sainz, Y.; Montoya, M.E.; Martinez-Crespo, F.J.; Ortega, M.A.; Lopez de Ceralin, A.; Monge, A. New quinoxaline 1,4-di-N-oxides for treatment of tuberculosis. Arzneim. Forsch/Drug Res. 1999, 49, 55-59.
172. Ortega, M.A.; Sainz, Y.; Montoya, M.E.; Lopez de Ceralin, A.; Monge, A. Synthesis and antituberculosis activity of new 2-quinoxalinecarbonitrile 1,4-di-N-oxides. Pharmazie, 1999, 54, 24-25.
173. Montoya, M.E.; Sainz, Y.; Ortega, M.A.; Lopez de Cerain, A.; Monge, A. Synthesis and antituberculosis activity of some quinoxaline carbonitriles. Il Farmaco, 1998, 55, 570-573.
174. Jaso, A.; Zarranz, B.; Aldana, I.; Monge A. Synthesis of new 2-actyl and 2-benzoyl quinoxaline 1,4-di -N-oxide derivatives as anti-Mycobacterium tuberculosis agents. Eur. J. Med. Chem., 2003, 38, 791-800.
175. Villar, R.; Vicente, E.; Solano, B.; Perez-Silanes, S.; Aldana, I.; Maddry, J. A.; Lenaerts, A.J.; Franzblau, S.G.; Cho, S.H.; Monge, A.; Goldman, R.C. In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide. J. Antimicrob. Chemother., 2008, 62, 547-554.
176. Zarranz, B.; Jaso, A.; Aldana, I.; Monge A. Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4- di-N-oxide derivatives. Bioorg. Med. Chem., 2003, 11, 2149-2156.
177. Moreno, E.; Ancizu, S.; Perez-Silanes, S.; Torres, E.; Aldana, I.; Monge A. Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives Eur. J. Med. Chem., 2010, 45, 4418-4426.
178. Ancizu, S.; Moreno, E.; Solano, B.; Villar, R.; Burguete, A.; Torres, E.; Perez-Silanes, S.; Aldana, I.; Monge A. New-3-methylquinoxaline-2-carboxamide 1,4-di-N-oxide derivatives as anti-Mycobacterium tuberculosis agents. Bioorg. Med. Chem., 2010, 18, 2713-2719.
179. Moreno, E.; Perez-Silanes, S.; Gouravaram, S.; Macharam, A.; Ancizu, S.; Torres, E.; Aldana, I.; Monge A.; Crawford, P. W. 1,4-di-N-oxide quinoxaline-2-carboxamide: cyclic voltammetry and relationship between electrochemical behavior, structure and anti-tuberculosis activity. Electrochim. Acta, 2011, 56, 3270-3275.
180. Jaso, A.; Zarranz, B.; Aldana, I.; Monge A. Synthesis of new quinoxaline-2-carboxyxlate 1,4-dioxide derivatives as anti- Mycobacterium tuberculosis agents. J. Med. Chem., 2005, 48, 2019-2025.
181. Vicente, E.; Villar, R.; Burguete, A.; Solano, B.; Perez-Silanes, S.; Aldana, I.; Maddry, J. A.; Lenaerts, A.J.; Franzblau, S.G.; Cho, S.H.; Monge, A.; Goldman, R.C. Antimicrob. Agents Chemother., 2008, 52, 3321-3326.
182. Vicente, E.; Duchowicz Castro, E.A.; Monge A. QSAR analysis for quinoxaline-2-carboxylate 1,4-di-N-oxides as anti-mycobacterial agents. J. Mol. Graph. Model., 2009, 28, 28-36.
183. Torres, E.; Moreno, E.; Ancizu, S.; Barea, C.; Galiano, S.; Aldana, I.; Monge, A.; Perez-Silanes, S. New 1,4-di-N-oxide quinoxaline- 2-ylmethylene isonicotinic acid hydrazide derivatives as anti- Mycobacterium tuberculosis agents. Bioorg. Med. Chem. Lett., 2011, 21, 3699-3703.
184. Vicente, E.; Perez-Silanes, S.; Lima, L.M.; Ancizu, S.; Burguete, A.; Solano, B.; Villar, R.; Aldana, I.; Monge, A. Selective activity against Mycobacterium tuberculosis of new quinoxaline 1,4-di-N-oxides. Bioorg. Med. Chem., 2009, 17, 385-389.
185. Tarallo, M.B.; Urquiola, C.; Monge, A.; Parajon Costa, B.; Ribeiro, R.R.; Costa-Filho, A.J.; Mercader, R.C.; Pavan, F.R.; Leite, C.Q.F.; Torre, M.H.; Gambino, D. Design of novel iron compounds as potential therapeutic agents against tuberculosis. J. Inorg. Biochem., 2010, 104, 1164-1170.
186. Vicente, E.; Villar, R.; Solano, B.; Burguete, A.; Ancizu, S.; Zarranz, B.; Jaso, A.; Marin, A.; Perez-Silanes, S.; Aldana, I.; Goldman, R.; Monge, A. Quinoxaline 1,4-di-N-oxide and the potential for treating Tuberculosis. Infect. Disord. Drug Targets, 2011, 11, 196-204.
187. Carta, A.; Paglietti, G.; Rahbar Nikookar, M.E.; Sanna, P.; Sechi, L.; Zanetti, S. Novel substituted quinoxaline 1,4-dioxides with in vitro antimycobacterial and anticandida activity. Eur. J. Med. Chem., 2002, 37, 355-366.
188. Carta, A.; Loriga, M.; Paglietti, G.; Mattana, A.; Fiori, P.L.; Molicotti, P.; Sechi, L.A.; Zanetti, S. Synthesis, anti-mycobacterial, anti-trichomonas and anti-candida in vitro activities of 2-substituted-6,7-difluoroquinoxaline 1,4- dioxides. Eur. J. Med. Chem., 2004, 39, 195-203.
189. Zanetti, S. Sechi, L.A.; Molicotti, P.; Cannas, S.; Bua, A.; Deriu, A.; Carta, A.; Paglietti, G. Int. J. Antimicrob. Agents. 2005, 25, 177-184.
190. Ancizu, S.; Moreno, E.; Torres, E.; Burguete, A.; Perez-Silanes, S.; Benitez, D.; Villar, R.; Solano, B.; Marin, A.; Aldana, I.; Cerecetto, H.; Gonzales, M.; Monge, A. Heterocyclic-2-carboxylic acid (3-cyano-1,4-di-N-oxidequinoxalin-2-yl)amide derivatives as hits for the development of negelected disease drugs. Molecules, 2009, 14, 2256-2272.
191. Vicente, E.; Duchowicz, P.R.; Del V., Ortiz, E.; Monge, A.; Castro, E.A. Exploring 3-arylquinoxaline-2- carbonitrile 1,4-di-N-oxides activities against neglected diseases with QSAR. Chem. Biol. Drug. Des., 2010, 76, 59-69.
192. Aguirre, G.; Cerecetto H.; Di Maio, R.; Gonzales, M.; Alvarez, G.; Montoya-Alfaro M.E.; Jaso, A.; Zarranz, B.; Angel Ortega M.; Aldana, I.; Monge-Vega, A. Quinoxaline N,N'-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi. Structure-activity relationships. Bioorg. Med. Chem. Lett., 2004, 14, 3835-3839.
193. Vicente, E.; Duchowicz, P.R.; Benitez, D.; Castro, E.A.; Cerecetto H.; Gonzales, M.; Monge Anti-T. Cruzi activities and QSAR studies of 3-arylquinoxaline-2-carbonitrile di-N-oxides. Bioorg. Med. Chem. Lett., 2010, 20, 4831-4835.
194. Estevez, Y.; Quiliano, M.; Burguete, A.; Cabanillas, B.; Zimic, M.; Malaga, E.; Verastegui, M.; Perez-Silanes, S.; Aldana, I.; Monge, A.; Castillo, D.; Deharo, E. Trypanocidal properties, structure-activity relationship and computational studies of quinoxaline 1,4-di-Noxide derivatives. Exp. Parasitol., 2011, 127, 745-751.
195. Urquiola, C.; Vieites, M.; Aguirre, G.; Marin, A.; Solano, B.; Arrambide, G.; Noblia, P.; Lavaggi, M.L.; Torre, M.H.; Gonzales, M.; Monge, A.; Gambino, D.; Cerecetto, H. Improving antitrypanosomal activity of 3-aminoquinoxaline-2-carbonitrile N1- N4-dioxide derivatives by complexation with vanadium. Bioorg. Med. Chem., 2006, 14, 5503-5509.
196. Benitez, D.; Lavaggi, M.L.; Gambino, D.; Torre, M.H.; Cerecetto, H.; Gonzales, M. Effect of complexation of 3-aminoquinoxaline-2- carbonitrile 1,4-dioxides with palladium and copper on their T. Cruzi activity. Med. Chem. Res., 2012, 21, 1439-1444.
197. Varela, J.; Alves Lessa, J.; Lavaggi, M.L.; Beraldo, H.; Cerecetto, H.; Gonzales, M. Coordination of 3-aminoquinoxaline-2- carbonitrile 1,4-dioxides to antimony (III) as a strategy for anti- Trypanosoma cruzi activity improvement. Med. Chem. Res., 2012, 21, 4120-4128.
198. Torre, M.H.; Gambino, D.; Araujo, J.; Cerecetto, H.; Gonzales, M.; Lavaggi, M.L.; Azqueta, A.; Lopez de Cerain, A.; Monge Vega, A.; Abram, U.; Costa-Filho, A.J. Novel Cu(II) quinoxaline- N1,N4-dioxide complexes as selective hypoxic cytotoxins. Eur. J. Med. Chem., 2005, 40, 473-480.
199. Vieites, M.; Noblia, P.; Torre, M.H.; Cerecetto, H.; Lavaggi, M.L.; Costa-Filho, A.J.; Azqueta, A.; Lopez de Cerain, A.; Monge, A.; Parajon-Costa, B.; Gonzales, M; Gambino, D. Selective hypoxia-cytotoxins based on vanadyl complexes with 3- aminoquinoxaline-2-carbonitrile-N1,N4-dioxide complexes. J. Inorg. Biochem., 2006, 100, 1358-1367.
200. Urquiola, C.; Vieites, M.; Torre, M.H.; Cabrera, M.; Lavaggi, M.L.; Cerecetto, H.; Gonzales, M.; Lopez de Cerain, A.; Monge, A.; Smircich, P.; Garat, B.; Gambino, D. Cytotoxic palladium complexes of bioreductive quinoxaline N1,N4-dioxide prodrugs. Bioorg. Med. Chem., 2009, 17, 1623-1629.
201. Noblia, P.; Vieites, M.; Torre, M.H.; Costa-Filho, A.J.; Cerecetto, H.; Gonzales, M.; Lavaggi, M.L.; Adachi, Y.; Sazkurai, H.; Gambino, D. Novel vanady complexes with quinoxaline N1,N4-dioxide derivatives as potent in vitro insulin-mimetic compounds. J. Inorg. Biochem., 2006, 100, 281-287.
202. Urquiola, C.; Gambino, D.; Lavaggi, M.L.; Cerecetto, H.; Gonzales, M; Lopez de Cerain, A.; Monge, A.; Costa-Filho, A.J.; Torre, M.H. New copper-based complexes with quinoxaline N1,N4-dioxide derivatives, potential antitumoral agents. J. Inorg. Biochem., 2008, 102, 119-126.
203. Romeiro, N.C.; Aguirre, G.; Hernandez, P.; Gonzales, M.; Cerecetto, H.; Aldana, I.; Perez-Silanes, S.; Monge, A.; Barreiro, E.J.; Lima, L.M. Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates. Bioorg. Med. Chem., 2009, 17, 641-652.
204. Benitez, D.; Cabrera, M.; Hernandez, P.; Boiani, L.; Lavaggi, M.L.; Di Maio, R.; Yaluff, G.; Serna, E.; Torres, S.; Ferreira, M.E.; Vera de Bilbao, N.; Torres, E.; Perez-Silanes, S.; Solano, B.; Moreno, E.; Aldana, I.; Lopez de Cerain, A.; Cerecetto, H.; Gonzales, M.; Monge, A. 3-trifluoromethylquinoxaline N,N'-dioxides as antitripanosomatid agents. Identification of optimal anti T. Cruzi agents and mechanism of action studies. J. Med. Chem., 2011, 54, 3624-3636.
205. Aguirre, G.; Boiani, M.; Cerecetto, H.; Gerpe, A.; Gonzales, M.; Fernandes Sainz, Y.; Denicola, A.; Ochoa de Ocariz, C.; Nogal, J.J.; Montero, D.; Escario, J.A. Novel antiprotozaol products; imidazole and benzimidazole N-oxide derivatives and related compounds. Arch. Pharm. Pharm. Med. Chem., 2004, 337, 259-270.
206. Boiani, M.; Boiani, L.; Denicola, A.; Torres de Ortiz, S.; Serna, E.; Vera de Bilbao, N.; Sanabria, L.; Yaluff, G.; Nakayama, H.; Rojas de Arias, A.; Vega, C.; Rolan, M., Gomez-Barrio, A.; Cerecetto, H.; Gonzales, M. 2H-benzimidazole 1,3-dioxide derivatives: a new family of water-soluble anti-trypanosomatid agents. J. Med. Chem., 2006, 49, 3215-3224.
207. Boiani, M.; Boiani, L.; Merlino, A.; Hernandez, P.; Chidichimo, A.; Cazzulo, J.J.; Cerecetto, H.; Gonzales, M. Second generation of 2Hbenzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: synthesis, biological evaluation and mode of action studies. Eur. J. Med. Chem., 2009, 44, 4426-4433.
208. Gerpe, A.; Aguirre, G.; Boiani, L.; Cerecetto, H.; Gonzales, M.; Olea-Azar, C.; Rigol, C.; Maya, J.D.; Morello, A.; Piro, O.E.; Aran, V.J.; Azquera, A.; Lopez de Cerain, A.; Monge, A.; Rojas, M.A.; Yaluff, G. Indazole N-oxide derivatives as antiprotozoal agents: synthesis, bilogical evaluation and mechanism of action studies. Bioorg. Med. Chem., 2006, 14, 3467-3480.
209. Lavaggi, M.L.; Aguirre, G.; Boiani, L.; Orelli, L.; Garcia, B.; Cerecetto, H.; Gonzales, M. Pyrimido[1,2-a]quinoxaline 6-oxide and phenazine 5,10-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi. Eur. J. Med. Chem., 2008, 43, 1737-1741.
210. Monge, A.; Palop, J.A.; Lopez de Cerain, A.; Senador, V.; Martinez-Crespo, F.J.; Sainz, Y.; Narro, S.; Garcia, E.; de Miguel, C.; Gonzalez, M.; Hamilton, E.; Barker, A.J.; Clarke, E.D.; Greenhow, D.T. Hypoxia-Selective Agents derived from quinoxaline 1,4-di-N-oxides. J. Med. Chem., 1995, 38, 1786-1792.
211. Monge, A.; Martinez-Crespo, F.J.; Lopez de Cerain, A.; Palop, J.A.; Narro, S.; Senador, V.; Marin, A.; Sainz, Y.; Gonzalez, M.; Hamilton, E.; Barker, A.J. Hypoxia-Selective Agents derived from 2-quinoxalinecarbonitrile 1,4-di-N-oxides. 2. J. Med. Chem., 1995, 38, 4488-4494.
212. Monge, A.; Palop, J.A.; Gonzalez, M.; Martinez-Crespo, F.J.; Lopez de Cerain, A.; Sainz, Y.; Narro, S.; Barker, A.J.; Hamilton, E. New Hypoxia-selective cytotoxines derived from quinoxaline 1,4-dioxides. J. Heterocyclic Chem. 1995, 32, 1213-1217.
213. Zamalloa, E, Aldana, I, Bachiller, C.M.; Monge, A. Physochemical properties and stability of the new hypoxiaselective agent 7-chloro-3-((N,N-dimethylamino)propylamino)-2- quinoxalinecarbonitrile 1,4-di-N-oxide hydrochloride. Arzneim. Forsch/Drug Res. 1997, 47, 873-878.
214. Martinez-Crespo, F.J.; Palop, J.A.; Sainz, Y.; Narro, S.; Senador, V.; Gonzalez, M.; Lopez de Cerain, A.; Monge, A.; Hamilton, E.; Barker, A.J. 4-cynao-2-oxo-1,2,4-oxadiazolo(2,3-a)quinoxaline 5-Noxides. New synthetic method and reaction with alcohols. Potential cytotoxic activity. J. Heterocyclic Chem. 1996, 33, 1671-1677.
215. Ortega, M.A.; Morancho, M.J.; Martinez-Crespo, F.J.; Sainz, Y.; Montoya, M.E.; Lopez de Cerain, A.; Monge, A. New quinoxalinecarbonitrile 1,4-di-N-oxide derivatives as hypoxiccytotoxic agens. Eur. J. Med. Chem., 2000, 35, 21-30.
216. Ganley, B.; Chowdhury, G.; Bhansali, J.; Daniels, J.S.; Gates, K.S. Redox-activated, Hypoxia-selective DNA cleavage by quinoxaline-1,4-di-N-oxide. Bioorg. Med. Chem., 2001, 9, 2395-2401.
217. Chowdhury, G.; Kotandeniya, D.; Daniels, J.S.; Barnes, C.L.; Gates, K.S. Enzyme-activated, Hypoxia-selective DNA cleavage by 3-amino-2-quinoxaline-1,4-di-N-oxide. Chem. Res. Toxicol. 2004, 17, 1399-1405.
218. Amin, K.M.; Ismail, M.M.F.; Noaman, E.; Soliman, D.H.; Ammar, Y.A. New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-Noxides. Bioorg. Med. Chem., 2006, 14, 6917-6923.
219. Sheng, R.; Xu, Y.; Weng, Q.; Xia, Q.; He, Q.; Yang, B.; Hu, Y. Synthesis and cytoxic activity of 3-phenyl-2-thio-quinoxaline 1,4- dioxide derivatives in hypoxia and in normoxia. Drug. Discov. Ther., 2007, 1, 119-123.
220. Weng, Q.; Wang, D.; Guo, P.; Fang, L.; Hu, Y.; He, Q.; Yang, B. Q39, a novel synthetic quinoxaline 1,4-dioxide compound with anti-cancer activity in hypoxia. Eur. J. Pharmacol., 2008, 581, 262-269.
221. Weng, Q.; Zhang, J.; Cao, J.; Xia, Q.; Wang, D.; Hu, Y.; Sheng, R.; Wu, H.; Zhu, H.; He, Q.; Yang, B. Q39, a quinoxaline 1,4-dioxide derivative, inhibits-inducible factor-1 expression and the Akt/mTOR/4E-BP1 signaling pathway in human hepatoma cells. Invest. New Drugs, 2011, 29, 1177-1187.
222. Gali-Muhtasib, H.; Sidani, M.; Geara, F.; Mona, A-D.; Al- Hmaira, J.; Haddadin, M.J.; Zaatari, G. Quinoxaline 1-4-dioxides are novel angiogenesis inhibitors that potentiate antitumor effects of ionizing radiation. Int. J. Onc., 2004, 24, 1121-1131.
223. Hu, Y.; Xia, Q.; Shangguan, S.; Liu, X.; Hu, Y.; Sheng, R. Synthesis and biological evaluation of 3-arylquinoxaline-2- carbonitrile 1,4-di-N-oxide derivatives as hypoxic selective antitumor agents. Molecules, 2012, 17, 9683-9696.
224. Junnotula, V.; Rajapakse, A., Arbillaga, L.; Lopez de Cerain, A.; Solano, B.; Villar, R.; Monge, A.; Gates, K.S. DNA strand cleaving properties and hypoxia-selective cytotoxicity of 7-chloro- 2-thienylcarbonyl-3-trifluoromethylquinoxaline 1,4-dioxide. Bioorg. Med. Chem., 2010, 18, 3125-3132.
225. Cerecetto, H.; Gonzalez, M.; Lavaggi, M.L.; Azqueta, A.; Lopez de Cerain, A.; Monge, A. Phenazine 5,10-dioxide derivatives as hypoxic selective cytotoxins. J. Med. Chem., 2005, 48, 21-23.
226. Cerecetto, H.; Gonzalez, M.; Lavaggi, M.L.; Aravena, M.A.; Rigol, C.; Olea-Azar, C.; Azqueta, A.; Lopez de Cerain, A.; Monge, A.; Bruno, A.M. Phenazine 5,10-dioxide derivatives as hypoxic selective cytotoxins: Part II. Structure-Activity relationship studies. Med. Chem., 2006, 2, 511-521.
227. Lavaggi, M.L.; Cabrera, M.; Gonzalez, M.; Cerecetto, H. Differential reductions governing the differential hypoxia-selective cytotoxicities of phenazine 5,10-dioxides. Chem. Res. Toxicol., 2008, 21, 1900-1906.
228. Corcuera, L.A.; Lavaggi, M.L.; Arbillaga, L.; Pachon, G.; Cascante, M.; Cerecetto, H.; Gonzalez, M.; Lopez de Cerain, A. Genotoxicity and oxidative DNA damage of phenazine 5,10- dioxides as bioreductive prodrugs for solid tumour treatment. Toxicol. Lett., 2010, 196, S170.
229. Nagai, K.; Carter, B.J.; Xu, J.; Hecht, S. M. DNA cleavage by oxygen radicals produced in the absence of metal ions or light. J. Am. Chem. Soc., 1991, 113, 5099-5100.
230. Lavaggi, M.L.; Cabrera, M.; de los Angeles Aravena, M.; Olea-Azar, C.; Lopez de Cerain, A.; Monge, A.; Pachon, G.; Cascante, M.; Bruno, A.M.; Pietrasanta, L.I.; Gonzalez, M.; Cerecetto, H. Study of benzo[a]phenazine 7,12-dioxide as selective hypoxidc cytotoxin-scaffold. Identification of aerobic-antitumoral activity through DNA fragmentation. Bioorg. Med. Chem., 2010, 18, 4433-4440.
231. Pachon, G.; Azqueta, A.; Lavaggi, M.L.; Lopez de Cerain, A.; Creppy, E.; Collins, A.; Cerecetto, H.; Centelles, J.J.; Cascante, M. Antitumoral effect of phenazine N5-N10-dioxide derivatives on caco-2 cells. Chem. Res. Toxicol., 2008, 21, 1578-1585.
232. Lavaggi, M.L.; Nieves, M.; Cabrera, M.; Olea-Azar, C.; Lopez de Cerain, A.; Monge, A.; Gonzalez, M.; Cerecetto, H.; Gonzalez, M. Structural modifications on the phenazine N,N'-dioxide-scaffold looking for new selective cytotoxins. Eur. J. Med. Chem., 2010, 45, 5362-5369.
233. Nagai, K.; Hecht, S. M. Site-specific DNA-cleavage by antisense oligonucleotides covalently linked to phenazine Di-Noxide. J. Biol. Chem., 1991, 266, 23994-24002.
234. Helissey, P.; Giorgi-Renault, S.; Colson, P.; Houssier, C.; Bailly, C. Sequence recognition and cleavage of DNA by a netrospin-phenazine-di-Noxide conjugate. Bioconjugate Chem., 2000, 11, 219-227.
235. Zarranz, B.; Jaso, A.; Aldana, I.; Monge, A. Synthesis and anticancer activity evaluation of new 2-alkylcarbonyl and 2- benzoyl-3-trifluoromethyl-quinoxaline 1,4-di-N-oxide derivatives. Bioorg. Med. Chem., 2004, 12, 3711-3721.
236. Solano, B.; Junnotula, V.; Marin, A.; Villar, R.; Burguete, A.; Vicente, E.; Perez-Silanes, S.; Aldana, I.; Monge, A.; Dutta, S.; Sarkar, U.; Gates, K.S. Synthesis and biological evaluation of new 2-arylcarbonyl-3-trifluoromethylquinoxaline 1,4-di-N-oxide derivatives and their reduced analogues. J. Med. Chem., 2007, 50, 5485-5492.
237. Azqueta, A.; Gil, A.G.; Garcia-Rodriguez, A.; Garcia-Jalon, J.A.; Cia, F.; Zarranz, B.; Monge, A.; Lopez de Cerain, A. Comparative Acute systemic toxicity of several quinoxaline 1,4-di-N-oxides in wistar rats. Arzneim. Forsch/Drug Res., 2007, 57, 339-346.
238. Wang, Z., Zhang, W.; Wang, Y.L., Ihsan, A.; Dai, M.H.; Huang, L.L.; Chen, D.M.; Tao, Y.F.; Peng, D.P.; Liu, Z.L.; Yuan, Z. H. Two generation reproduction and teratogenicity studies of feeding quinocetone fed to Wistar rats. Food Chem. Toxicol., 2012, 50, 1600-1609.
239. Liu, J.; Ouyang, M.; Jiang, J.; Mu, P.; Wu, J.; Yang, Q.; Zhang, C.; Xu, W.; Wang, L.; Huen, M.S.Y.; Deng, Y. Mequindox induced cellular DNA damage via generation of reactive oxygen species. Mut. Res., 2012, 741, 70-75.
240. Monge, A.; Palop, J.A.; Urbasos, I.; Fernandez-Alvarez, E. New quinoxaline and pyrimido[4,5-b] quinoxaline derivatives. Potential antihypertensive and blood platelet antiaggregating agents. J. Het. Chem., 1989, 26, 1623-1626.
241. Ibrahim, I.T.; Wally, M.A. Synthesis, labeling and biodistribution of 99mTc-3-amino-quinoxaline-carbonitrile 1,4-dioxide in tumor bearing mice. J. Radioanal. Nucl. Chem., 2010, 285, 169-175.
242. Burguete, A.; Pontiki, E.; Hadjipavlou-Litina, D.; Villar, R.; Vicente, E.; Solano, B.; Ancizu, S.; Perez-Silanes, S.; Aldana, I.; Vivas, L.; Monge, A. Synthesis and anti-inflammatory/antioxidant activities of some new ring substituted 3-phenyl-1-(1,4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one derivatives and of their 4,5- dihydro-(1H)-pyrazole analogues. Bioorg. Med. Chem. Lett., 2007, 17, 6439-64443.
243. Das, U.; Pati, H.N.; De Clercq, E.; Balzarini, J.; Molnar, J.; Barath, Z.; Ocsovszki, I.; Kawase, M.; Zhou, L.; Sakagami, H.; Dimmock, J. R. 2-(3-aryl-2-propenoyl)-3-methylquinoxaline-1,4-dioxides have been used as novel cluster of tumor-specific cytotoxins which reverse multidrug resistance. Bioorg. Med. Chem., 2009, 17, 3909-3915.